STEP HFpEF: GLP-1s for Obesity-Related Heart Failure

STEP HFpEF established semaglutide as effective for obesity-phenotype HFpEF. Here's the trial design, results, and what it changed in heart failure practice.

STEP HFpEF was the first dedicated heart failure outcomes trial of a GLP-1 receptor agonist and focused on patients with the obesity phenotype of heart failure with preserved ejection fraction (HFpEF). Published in 2023, the trial established that semaglutide 2.4 mg improves symptoms, functional capacity, and quality of life in obesity-related HFpEF — a patient population that had historically been difficult to treat pharmacologically.

Trial Design

STEP HFpEF enrolled 529 adults with HFpEF (LVEF ≥45%) and BMI ≥30. Participants were randomized to weekly subcutaneous semaglutide 2.4 mg or placebo for 52 weeks. The dual primary endpoints were change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (a validated patient-reported heart failure outcome measure) and change in body weight. Secondary endpoints included 6-minute walk distance, C-reactive protein, and NT-proBNP.

Primary Results

Both primary endpoints were met with high statistical significance. The KCCQ improvement of ~8 points beyond placebo is clinically meaningful — approximately double the threshold typically considered clinically important in heart failure trials.

STEP HFpEF DM: The Diabetes Subpopulation

STEP HFpEF DM was a companion trial that enrolled patients with HFpEF, obesity, and type 2 diabetes. It extended the STEP HFpEF findings into the diabetic population and confirmed that the heart failure symptom and functional benefits of semaglutide persist when patients have concurrent diabetes. Combined with STEP HFpEF, the evidence now covers the obesity-HFpEF phenotype both with and without diabetes.

Mechanism Speculation

How semaglutide improves HFpEF symptoms is not fully understood. Weight loss itself reduces cardiac workload, improves diastolic function, and reduces systemic inflammation — all relevant to HFpEF pathophysiology. Direct effects of GLP-1 receptor activation on cardiac tissue, anti-inflammatory effects, improved endothelial function, and reduced epicardial fat have all been proposed as additional mechanisms. The mechanistic picture is consistent with a multi-pathway benefit rather than a single dominant mechanism.

Clinical and Guideline Impact

STEP HFpEF has influenced heart failure clinical practice guidelines, which now recognize GLP-1 receptor agonists as a consideration for patients with obesity-phenotype HFpEF. This is the first time the obesity phenotype of HFpEF has had a dedicated pharmacologic therapy with high-quality trial evidence, and it has reframed how heart failure specialists think about obesity as a modifiable contributor to HFpEF rather than just a comorbidity.

What STEP HFpEF Does Not Establish

The trial was not powered for hard cardiovascular endpoints like heart failure hospitalization or cardiovascular death. It was designed to establish symptomatic and functional benefit, which it did. Ongoing programs — including larger outcomes trials and HFpEF programs for tirzepatide — are testing whether the symptomatic benefit translates into reduced heart failure hospitalizations and mortality.

Relationship to SELECT

SELECT showed cardiovascular event reduction in patients with established atherosclerotic cardiovascular disease. STEP HFpEF showed symptomatic heart failure benefit in a different cardiovascular population (HFpEF, often without atherosclerotic disease). Together, they support semaglutide's cardiovascular utility across multiple cardiovascular phenotypes. For related reviews, see our SELECT trial review and FLOW trial review.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.